ASCO Annual Meeting

According to the authors, these data reinforce EV plus pembrolizumab as the first-line standard of care for la/mUC.

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.

"There was activity across all the groups from an EFS perspective," said Thomas B. Powles, MBBS, MRCP, MD.

The cCR rate was 44.4% in the intent-to-treat population.

Vitaly Margulis, MD, reported an overall response rate of 86.5%, and a complete response rate of 73%.

At a median follow-up of 61.4 months, enzalutamide plus ADT continued to show an improvement in OS vs ADT alone.

Hayne finds the emergence of antibody drugs conjugates in urothelial cancer to be particularly intriguing.

This year's meeting with feature several notable sessions in prostate cancer, bladder cancer, kidney cancer, and other GU malignancies.

“Over the 4-year period since first-line protocol therapy initiation, [patients treated with] nivolumab plus cabozantinib achieved a 1.5-times longer mean TFS vs sunitinib," says Charlene Mantia, MD.

“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.

No statistically significant difference was seen in progression-free survival among those who received metformin vs those who received placebo.

“I think my immediate hope and goal with the study finding is universal incorporation of HPV testing on all penile cancer patients,” says Rohan Garje, MD.

“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.

Results presented from a phase 1/2 trial of ARV-766 demonstrated efficacy and tolerability in patients whose metastatic castration-resistant prostate cancer progressed after androgen receptor pathway inhibitor therapy.

“The results of the study showed that regardless of any biomarkers, the combination of pembrolizumab and lenvatinib was superior or associated with a better median progression-free survival compared to sunitinib,” says Jaime R. Merchan, MD.

Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.

“We can see that the median survival is going beyond 31 months, meaning that patients with a low tumor burden are benefiting,” says Joaquim Bellmunt, MD, PhD.

“The PRO data presented here complements the published clinical efficacy and safety data, add the patient's voice, and support the use of EV/pembro for patients with locally advanced/metastatic urothelial cancer," says Shilpa Gupta, MD.

Updated findings from cohort H of the EV-103 study showed promising 2-year event-free survival outcomes and favorable antitumor activity with enfortumab vedotin in cisplatin-ineligible patients with muscle-invasive bladder cancer.

A post-hoc analysis of the phase 3 ARAMIS trial provided additional efficacy evidence for darolutamide in nmCRPC, including benefits related to prostate cancer–specific survival and reaching a PSA level <0.2 ng/mL.

Patients with advanced renal cell carcinoma treated with TKIs in the second or third line following lenvatinib treatment showed modest activity, highlighting the need for improved treatment options.

A retrospective cohort of patients with metastatic urothelial cancer who received prior enfortumab vedotin had low efficacy when treated with sacituzumab govitecan, with the best outcomes coming from directly sequencing the 2 agents.

“For patients who received darolutamide plus ADT and docetaxel, minimal differences in post-progression survival were observed between first subsequent therapies," said Marc-Oliver Grimm, MD.

"There is a hypothesis that nectin-4 as a potential target for antibody drug conjugates, such as EV, potentially should work," says Marijo Bilusic, MD, PhD.

In the EMBARK trial in patients with nonmetastatic hormone-sensitive prostate cancer, patients with good PSA responses at 37 weeks had their treatment suspended until their PSA started to rise again.

“So, we split this apart and looked into if the type of progression would occur differently depending on the organ sites, which it did not. What we have seen is maintained benefits for the combination of lenvatinib and pembrolizumab vs sunitinib,” says Viktor Grünwald, MD, PhD.

Adding cabazitaxel to abiraterone acetate and prednisone significantly reduced the risk of disease progression or death in patients with mCRPC previously treated with ADT plus docetaxel for HSPC.

This monotherapy was safe for all doses and dosing schedules observed in the study and daily doses showed initial antitumor activity.